Curasight A/S submits clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients
· Company on track to dose first patient in 2Q 2024 · CTA marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Copenhagen, December 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced submission of clinical trial application (CTA) to the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.The CTA was submitted under the new application